High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
202.35M
+10.97%
0.168
-11.38%
198.31M
+8.04%
0.184
+8.1%
201.12M
+6.33%
0.195
-27.76%
Estimates Revision
The market is revising Downward the revenue expectations for Sabra Health Care REIT, Inc. (SBRA) for FY2025, with the revenue forecasts being adjusted by -2.49% over the past three months. During the same period, the stock price has changed by 0.11%.
Revenue Estimates for FY2025
Revise Downward
-2.49%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-13.54%
In Past 3 Month
Stock Price
Go Up
+0.11%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast SBRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBRA is 20.33 USD with a low forecast of 20.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
6 Hold
0 Sell
Hold
Current: 19.050
Low
20.00
Averages
20.33
High
22.00
Current: 19.050
Low
20.00
Averages
20.33
High
22.00
Wells Fargo
Overweight
maintain
$20 -> $21
2025-11-25
Reason
Wells Fargo
Price Target
$20 -> $21
2025-11-25
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Sabra Health Care to $21 from $20 and keeps an Overweight rating on the shares. The firm says that despite a few high-profile exceptions, most REITs delivered Q3 2025 earnings and outlooks reflecting healthy operating conditions despite macro and labor market concerns.
UBS
Neutral
initiated
$20
2025-11-18
Reason
UBS
Price Target
$20
2025-11-18
initiated
Neutral
Reason
UBS initiated coverage of Sabra Health Care with a Neutral rating and $20 price target. The company should benefit from demographic tailwinds, a favorable skilled nursing facility backdrop, and expanding rent coverage ratios, the analyst tells investors in a research note. However, the firm believes this is already priced into the shares.
Wells Fargo
Overweight
downgrade
$21 -> $20
2025-10-21
Reason
Wells Fargo
Price Target
$21 -> $20
2025-10-21
downgrade
Overweight
Reason
Wells Fargo lowered the firm's price target on Sabra Health Care to $20 from $21 and keeps an Overweight rating on the shares. The firm remains most constructive on Senior Housing as market data continues to signal strength in occupancy and rate, and broker contracts flag accelerated deal volumes.
BofA
Buy
maintain
$21 -> $22
2025-10-17
Reason
BofA
Price Target
$21 -> $22
2025-10-17
maintain
Buy
Reason
BofA raised the firm's price target on Sabra Health Care (SBRA) to $22 from $21 and keeps a Buy rating on the shares. A "silver tsunami' in the U.S. is expected to to drive big gains for the major players in the senior housing business as Boomers age into senior living, says the analyst, who forecasts that margins for the five SHOP REITs- Welltower (WELL), Ventas (VTR), Sabra, American Healthcare REIT (AHR) and National Health Investor (NHI) - will expand ahead of Street estimates in 2026.
Cantor Fitzgerald
Richard Anderson
Neutral
initiated
$20
2025-10-01
Reason
Cantor Fitzgerald
Richard Anderson
Price Target
$20
2025-10-01
initiated
Neutral
Reason
Cantor Fitzgerald analyst Richard Anderson initiated coverage of Sabra Health Care with a Neutral rating and $20 price target. The firm initiated coverage of the U.S. REITs, including nine property sectors and 40 stocks. Although there isn't widespread enthusiasm for a REIT recovery in 2026 just yet, Cantor believes the industry could be well-positioned over the next 12 to 24 months, the analyst tells investors in a research note. The firm's top property sector calls include Office, Industrial, Healthcare and Net Lease, but is incrementally more cautious on Multifamily and Hotels.
Truist
Michael Lewis
Hold
maintain
$18 -> $20
2025-09-03
Reason
Truist
Michael Lewis
Price Target
$18 -> $20
2025-09-03
maintain
Hold
Reason
Truist analyst Michael Lewis raised the firm's price target on Sabra Health Care to $20 from $18 and keeps a Hold rating on the shares. The REIT has a strong balance sheet and the stock has performed well year-to-date, though the company is not as low levered as several peers and, despite trading near the high end of its 10-year stock valuation range, its current cost of equity leaves relatively little room for immediate earnings accretion, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sabra Health Care REIT Inc (SBRA.O) is 25.70, compared to its 5-year average forward P/E of 27.36. For a more detailed relative valuation and DCF analysis to assess Sabra Health Care REIT Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
27.36
Current PE
25.70
Overvalued PE
57.42
Undervalued PE
-2.71
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
13.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.26
Undervalued EV/EBITDA
12.28
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.26
Current PS
0.00
Overvalued PS
5.96
Undervalued PS
4.55
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SBRA News & Events
Events Timeline
(ET)
2025-11-05
16:10:45
Sabra Health Care projects 2025 adjusted FFO between $1.495 and $1.505, in line with consensus of $1.50
2025-11-05
16:09:58
Sabra Health Care announces Q3 adjusted FFO of 38 cents, matching expectations.
2025-08-20 (ET)
2025-08-20
09:13:45
Sunshine Retirement Living Partners with Sabra Health Care
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/496d6a991166fb0c5bc33998238196b5e81fdf8162fd331d79a33928c11def69.png)
Preview
6.0
11-19Yahoo FinanceUBS Begins Coverage of Sabra Health Care REIT, Assigns Neutral Rating and $20 Price Target
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/315576b1903a545e26a24ce09194c117d5ec963d30a992108b6a565106c8cbcc.png)
Preview
6.0
11-18BenzingaLumentum Analyst Starts Coverage Optimistically; Check Out Tuesday's Top 5 Initiations
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
6.0
11-18BenzingaUBS Begins Coverage of Sabra Health Care REIT with Neutral Rating and Sets Price Target at $20
Sign Up For More News
People Also Watch
FAQ
What is Sabra Health Care REIT Inc (SBRA) stock price today?
What is Sabra Health Care REIT Inc (SBRA)'s business?
What is the price predicton of SBRA Stock?
What is Sabra Health Care REIT Inc (SBRA)'s revenue for the last quarter?
What is Sabra Health Care REIT Inc (SBRA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Sabra Health Care REIT Inc (SBRA)'s fundamentals?
How many employees does Sabra Health Care REIT Inc (SBRA). have?